{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:10:39Z","timestamp":1789398639785,"version":"build-2803163510"},"reference-count":19,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100028612","name":"Kaiser Permanente Division of Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100028612","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bladder Cancer"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>We sought to characterize concordance of surveillance and treatment patterns in a large community-based healthcare system with the American Urologic Association\/Society of Urologic Oncology (AUA\/SUO) guideline for low- and intermediate-risk non-muscle invasive bladder cancer (NMIBC). We expect the results of this study to improve the oncologic care of patients with NMIBC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective cohort study of patients aged 18 years or older diagnosed with low- or intermediate-risk NMIBC between 1\/1\/2018 and 12\/31\/2022 and followed until 12\/31\/2024. The prevalence of single-dose post-operative intravesical chemotherapy instillations, cystoscopy procedures, and urine cytology tests were used to determine at, below, and above guideline-concordance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 631 low-risk and 619 intermediate-risk NMIBC patients were identified. Prevalences of single-dose immediate postoperative intravesical chemotherapy were: 35.2% (low-risk) and 36.8% (intermediate-risk). In the low-risk NMIBC group, average guideline-concordance was 47.5% for cystoscopy and 82.3% for cytology. In the intermediate-risk group, average guideline-concordance was 54.1% for cystoscopy and 27.2% for cytology. Percent of cystoscopy procedures exceeding guideline-concordance was 30.5% and 14.5% in the low- and intermediate-risk NMIBC groups, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Although guideline-concordance of single-dose intravesical instillations, cystoscopy procedures, and cytology tests mirrored what is reported in the literature, the prevalence of cystoscopy and cytology tests exceeding guideline-concordance was notably less, which may be a feature of our integrated delivery and finance system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Understanding the current landscape of concordance with the AUA\/SUO guideline is necessary for every healthcare delivery system to optimize the oncologic care of patients with NMIBC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/23523735261487765","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T11:24:38Z","timestamp":1789125878000},"source":"Crossref","is-referenced-by-count":0,"title":["Guideline-recommended post-operative intravesical chemotherapy and cystoscopic surveillance among patients with low- and intermediate-risk non-muscle invasive bladder cancer"],"prefix":"10.1177","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3737-6667","authenticated-orcid":false,"given":"Michael J.","family":"Shulman","sequence":"first","affiliation":[{"name":"Kaiser Permanente Roseville Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie S.","family":"Lee","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Northern California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janise M.","family":"Roh","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Northern California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilyn L.","family":"Kwan","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Northern California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003846"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2022.12.009"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01188-6"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.06.049"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30874-7"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03262330"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.3050"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2017.12.016"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26198"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2017.10.049"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32185"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.4657"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2025.08.032"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16780"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.06.025"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-58809-x"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2019.04.036"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-019-05594-3"}],"container-title":["Bladder Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23523735261487765","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/23523735261487765","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23523735261487765","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T14:46:27Z","timestamp":1789397187000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/23523735261487765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1177\/23523735261487765"],"URL":"https:\/\/doi.org\/10.1177\/23523735261487765","relation":{},"ISSN":["2352-3727","2352-3735"],"issn-type":[{"value":"2352-3727","type":"print"},{"value":"2352-3735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"article-number":"23523735261487765"}}